A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biol Blood Marrow Transplant 2020 Dec;26(12):e305-e308
Date
09/14/2020Pubmed ID
32920205Pubmed Central ID
PMC7735536DOI
10.1016/j.bbmt.2020.08.029Scopus ID
2-s2.0-85092101705 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Effective immunosuppressive regimens to prevent the development of graft-versus-host disease (GVHD) are essential to the success of allogeneic hematopoietic cell transplantation (HCT). After revolutionizing haploidentical transplantation, post-transplantation cyclophosphamide (PTCy) is now being evaluated for HCT performed from related and unrelated donors. In this setting, 2 recent randomized studies have demonstrated lower rates of GVHD and superior GVHD-free, relapse-free survival with PTCy compared with conventional GVHD prophylaxis. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is currently conducting a large, randomized phase III, multicenter trial (BMT CTN 1703) comparing PTCy/tacrolimus/mycophenolate mofetil to tacrolimus/methotrexate as GVHD prophylaxis regimens in reduced-intensity allogeneic HCT. Here we review the ongoing study, highlight its importance to the field, and explore the possible implications of its results on clinical practice.
Author List
DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera NAuthor
Samantha M. Jaglowski BS, MD, MPH, MBA Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Bone MarrowCyclophosphamide
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Multicenter Studies as Topic
Mycophenolic Acid
Randomized Controlled Trials as Topic
Transplantation Conditioning
Unrelated Donors









